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Introduction 
Pediatric bronchial asthma has been clinically 
recognized as a heterogeneous disease for decades, 
including descriptions of patients with allergy-
associated disease, viral induced asthma and 
exercise-induced asthma1.  
Despite this recognition, treatment approaches 
were similar, involving the use of nonspecific 
agents, such as inhaled corticosteroids (CS) and 
beta 2- agonists. These drugs, which were generally 
effective in the majority of asthmatic children, also 
failed in many. In each case, the molecular under-
pinnings of the heterogeneity or the varied 
responses to treatment were unknown2. 
In the middle of the 20th century, a significant 
increase in the prevalence of bronchial asthma (BA) 
was reported worldwide. This rise particularly 
referred to BA of pediatric onset; therefore asthma 
became one of the most prevalent chronic 
inflammatory diseases in pediatrics3.  
BA is described as a chronic inflammatory 
disorder of the airways with inflammatory 
symptoms causing a variable degree of airflow 
limitation and is accompanied by an increased 
sensitivity to multiple pharmacological and non-
pharmacological stimuli. The bronchial obstruction 
seen is often reversible, either spontaneously or 
with treatment4. 
BA is considered a complex disorder based on a 
multifactorial interaction of genetic predisposition 
and diverse environmental influences5.  
 
The Transition to "Asthma Molecular 
Immunological Endotypes" 
Recently, great progress has been made with regard 
to new insights into the heterogeneity of asthma on 
a molecular-biological level using unsupervised 
hierarchical clustering.  
Through molecular-immunological endotyping, 
a change of gene expression was identified, with the 
gene products representing potential biomarkers6. 
Clustering of asthmatic patients based on 
differential gene expression profiling from 
bronchial brushings and induced sputum samples 
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revealed at least three distinct asthma endotypes5; 
Classic and non-Classic TH 2 endotypes and non 
TH2 endotype7. 
Gene expression analysis was used to perform 
endotyping at a transcriptional level. mRNA was 
extracted from induced sputum of BA patients and 
gene expression was examined using whole-
genome microarray analysis genes were found to be 
differentially expressed in patients as compared 
with healthy controls8. In particular, gene 
expression profile was analyzed in the different 
subgroups through genome-wide profiling after 
isolation of mRNA and microarray evaluation. The 
analysis led to the identification of a panel of 
differentially expressed genes, which were strongly 
over-expressed in subjects with asthma compared 
with healthy controls, smokers and ICS-treated 
asthmatics. The genes that were most strongly 
induced in asthma were: 
- Chloride channel, calcium activated, family 
member 1 (CLCA1), (6.2 fold) 
- Serine peptidase inhibitor, clade B (ovalbumin), 
member 2 (SerpinB2) also known as plasminogen 
activator inhibitor-2 (PAI 2), (3.5 fold) 
- Periostin (POSTN), (4.4 fold) 
Validation of gene-expression was performed by 
PCR, and validation of protein expression was 
performed by immunostaining and enzyme-linked 
immunosorbent assay (ELISA). 
In order to obtain further information regarding 
the regulation of these genes, additional in vitro 
experiments were carried out on human respiratory 
epithelium, which showed that IL-13 induced the 
identified genes while dexamethasone prevented 
this effect or inhibited the gene expression8. 
 
TH2-high and TH2-low gene signatures and 
endotypes 
According to the preliminary molecular clustering 
studies of bronchial asthma, asthmatic children 
were further evaluated for the presence or absence 
of a TH 2 cytokine molecular signature. This TH 2 
molecular signature was first identified in vitro, in 
epithelial cell cultures, where three genes, periostin, 
CLCA1, and SERPINEB2, were found to be up-







Figure 1. Molecular Asthma Classification7 
 
The expression of this Type 2 molecular 
signature was then evaluated in freshly brushed 
epithelial cells obtained from mild, CS naïve 
asthmatics, where clear differences were observed 
in the presence or absence of this Type 2 signature. 
The Type 2 signature was present in only about 
50% of the mild asthmatics and was not seen in the 
non-atopic healthy controls. Whereas the absence of 
this Type 2 signature in many mild asthmatics was 
perhaps surprising, the presence of the signature 
was associated with relevant clinical and biological 
phenotypic characteristics, including more lung 
eosinophils and mast cells, higher IgE levels, more 
bronchial hyper-responsiveness, and, importantly, 
higher tissue expression of IL-5 and -1310. Similar 
to the association with tissue eosinophils reported in 
atopic asthma, the Type 2 signature was associated 
with a thicker subepithelial basement membrane, 
supporting considerable overlap between a Type 2 
cytokine molecular phenotype and the eosinophilic 
phenotypes. Importantly, the presence of this Type 
2 molecular signature also predicted a robust 
response to moderate-dose inhaled CS, whereas no 
response was seen in those without the Type 2 
cytokine signature11.  
This was linked to the traditional allergic clinical 
phenotype to an underlying Th2 signature (Fig. 
3A). As noted, in addition to tissue eosinophils, 
mast cells have also been reported in airway tissue 
in relation to Type 2 inflammation. Importantly, 
there is an increase in epithelial mast cells 
expressing the enzyme hematopoietic prostaglandin 
(PG) D synthase and its product PGD2. PGD2 
activates several receptors, one of which, chemo-
attractant receptor homologous molecule expressed 
on Th2 cells, is expressed on eosinophils, Th2 
lymphocytes, and, more recently, ILC2 cells, 
suggesting that mast cells/their products could 
integrate several cell types/pathways, including 
those related to innate immunity8. ILC2 cells are of 
particular interest for their role in Type 2 asthma, as 
they could both initiate and perpetuate Type 2 
cytokine responses, with some evidence for their 
existence in asthmatic airways; their importance in 
Type 2 asthma, however, remains unknown12. 
Importantly, however, the IL-33 pathway has been 
strongly linked to ILC2 cells. Polymorphisms in 
both IL-33 and its receptor, IL1RL1, have been 
consistently linked to early-onset allergic asthma in 
genome- wide association studies, consistent with a 
role in some Type 2 phenotypes13. 
Based on the above findings; it is suggested that 
products of the POSTN, CLCA1 and SERPINB2 
genes could serve as a surrogate marker for a TH2-
driven immune-response. The experiments and 
studies revealed that these three genes were over-
expressed only in a subset of asthmatics. To define 
this subset precisely, unsupervised hierarchical 
clustering was applied14 to the findings of the gene 
array analysis based on the expression level of the 
genes POSTN, CLCA1 and SERPINB2. 
Almost half of the subjects showed high 
expression level TH2-induced genes, while the 
other half exhibited a normal expression level. A 
comparison of all BA subjects and healthy controls 
revealed a general over-expression of the three 
genes. However after hierarchical clustering about 
half of the asthma-patients remained 
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Figure 2. Definitions for the transition from clinical phenotypes to molecular phenotypes to endotypes 
 
As a result the following two clusters could be 
separated; in cluster 1 the markers POSTN, CLCA1 
and SERPINB2 were highly up-regulated, which 
was not the case in cluster 2, representing the other 
half of the participants and the healthy controls. 
These studies together with additional analysis of 
the characteristics of airway inflammation helped to 
define the TH2-high and the TH2-low endotypes8.  
At one end of the spectrum it is possible to 
define an endotype with an up-regulated TH2 
response mediated by the typical TH2 cytokines IL-
5, IL-13 and IL-4 measured by the surrogate-
markers POSTN, CLCA1 and SERPINB2; and at 
the other end resides the endotype which is not 
associated with a TH2 response. This provides 
further evidence that the population of asthmatics is 
heterogeneous on a molecular level5. It has been 
suggested that the TH2 endotype shows a higher 
degree of bronchial hyper-reactiveness, higher 
serum IgE concentrations and a higher eosinophilia 
in blood and bronchoalveolar lavage (BAL). There 
is also a higher number of mast cells in the TH2 
endotype15. Patients with the TH2- endotype benefit 
from ICS treatment as measured by improvement of 
the FEV1, while the TH2-low subset is more 
resistant to steroid treatment16. 
Molecular endotyping obviously has important 
therapeutic implications. While the TH2 endotype, 
in particular the eosinophilic subtype, largely 
contains responders to steroid-treatment, TH2-low 
endotype asthma, which probably is consistent with 
the neutrophilic phenotype, is less understood with 
regard to the molecular pathogenesis17. Based on 
this concept, a randomized placebo-controlled study 
was held using a monoclonal antibody against IL-
13 (lebrikizumab), a prototypic TH2 cytokine, 
which is pathogenetically important in the TH2 
endotype. A total of 219 asthmatics were stratified 
according to TH2 endotype (high versus low) using 
serum periostin level as a surrogate marker of IL-13 
(and hence TH2 status). The primary endpoint was 
FEV1. Treatment with anti-IL-13 monoclonal 
antibody was given once a month for 6 months, 
with the result that when compared with placebo, 
there was a significant improvement in FEV1 only 
in the TH2-high endotype (p=0.03) which was not 
seen in the TH2-low endotype (p=0.61) 18. 
Periostin as a potential novel biomarker of a 
TH2 inflammation /as biomarker of a TH2 
endotype. 
Biological/physiological basics of periostin, 
inducibility and effects Periostin is a POSTN-gene 
encoded, disulfide bridge-bearing, 90 kDa, 
matricellular protein, which was originally isolated 
from osteoblasts and described as osteoblast-
specific factor 2.  Periostin is secreted into the 
extracellular matrix of the bronchial tissue, and not 
via the apical membrane into the lumen of the 
airway, which allows systemic measurement. 
Periostin is inducible in the airway epithelium by 
IL-4 and IL-1315 and is secreted by lung fibroblasts 
into the extracellular matrix11. 
Periostin is a matricellular protein, which 
contains a cysteine-rich domain at the N-terminal 
end and four repetitive fascillin- 1-domains and, 
therefore, belongs to the fascillin family18. Periostin 
functions as an adhesion molecule. It interacts with 
different integrin molecules on the cell surface such 
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as alpha-V/beta1, alpha-V/beta3 and alpha-V/beta5, 
and facilitates signals for tissue differentiation, 
growth and remodeling16. As a ligand for the 
mentioned integrins it supports cell adhesion and 
migration15. 
Furthermore it is a highly inducible product in 
lung fibroblasts following increased IL-4 and IL-13 
and plays a role in the development of fibrosis in 
asthma. Periostin directly regulates the 
accumulation of eosinophils in TH2-associated 
mucosal inflammation, also in the airways. 
Periostin enhances the emergence of fibrosis 
through binding to proteins of the extracellular 
matrix. Another effect of periostin is the counter-
regulation of mucus production. It was found that a 
POSTN-deficiency leads to an enhancement of the 
expression of Muc5ac and Gob5, and, consequently 
to an enhanced mucus production19. 
These novel observations suggest that periostin 
not only promotes inflammation. This is further 
supported by the observation that periostin can 
increase the production of IFN-gamma20. How these 
pro- and anti-inflammatory effects of periostin are 
regulated and controlled requires further study and 
whether periostin is important in the pathogenesis 
of other allergic conditions, or even in other chronic 
inflammatory diseases, steel needs to be 
investigated. 
 
Periostin as biomarker of TH2 inflammation 
Key question: 
Is it possible to use markers of TH2 inflammation 
as biomarkers for stratification prior to therapeutic 
interventions?  
A distinct eosinophilia is a reliable predictor for 
response to ICS. Particularly with regard to 
molecular-based therapies, differentiation in TH2-
high and TH2-low profiles is required and studies 
of mepulizumab and reslizumab (two monoclonal 
antibodies against the TH2 cytokine IL-5) 
demonstrate the importance and the benefit of 
selection of patients to obtain a clinically significant 
effect of treatment with targeted therapeutics21. 
There is recent evidence1 that periostin levels in 
serum are significantly increased in patients with 
asthma. This was found particularly for the 
eosinophilic type of airway inflammation compared 
with patients with only minimal eosinophilic airway 
inflammation. Periostin levels seem to correlate 
well with the TH2-high gene signature, and with the 
TH2 endotype.  
This leads to the question of whether serum 
periostin levels may serve as a good predictive 
parameter for stratifying patients prior to asthma 
treatment. 
The next important step is the development of 
reliable assay systems for such new biomarkers. For 
this purpose an ELISA assay for serum periostin is 
just developed1. The assay was tested in a variety of 
asthmatic patients, and significantly elevated serum 
periostin levels were found in a subset of asthmatics 
together with a correlation with eosinophilic airway 
inflammation. 
 
Although treatment with ICS has been found to 
reduce periostin levels as well as the airway 
eosinophilia in patients with mild-to moderate 
asthma, a subset of asthmatics showed persistent 
eosinophilic airway inflammation and symptoms 
despite high doses of ICS4. This subset could be 
divided into a subpopulation with sputum- or tissue-
eosinophilia (ensured by biopsy) and a 
subpopulation without these criteria (sputum 
eosinophils <3% and tissue eosinophils <22/mm2). 
The median periostin levels were significantly 
higher in individuals with high sputum- or tissue-
eosinophilia as compared with individuals with 
lower eosinophil counts. Individuals with a 
periostin level above a cut-off of 25 ng/mL had a 
greater than 85% risk of having an increased 
amount of eosinophils either in sputum or in 
bronchial tissue7. These eosinophil-low and 
eosinophil-high subpopulations could be 
distinguished by means of a periostin cut-off level 
of 25 ng/mL with a positive predictive value of 
93%21.  
These analyses may serve as a starting point for 
further investigation in order to establish periostin 
as a systemic biomarker of eosinophilic airway 
inflammation. 
Of all previously examined non-invasive 
biomarkers such as blood eosinophils, FeNO or 
IgE, periostin shows the highest probability as a 
predicator of a TH2-driven inflammation5. The 
ability of periostin to serve as a suitable biomarker 
for the identification of theTH2-endotype was 
illustrated in the previous study18 by Corren et al, in 
which 219 asthmatic patients were stratified into a 
TH2-high and a TH2-low-endotype as measured by 
their peripheral periostin levels. After treatment 
with lebrikizumab, an anti-IL-13 monoclonal 
antibody, subjects with a high peripheral periostin 
level showed a significant improvement in FEV1 
compared with placebo that was not observed in 
subjects with low periostin levels. 
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A: Traditional (classical) TH 2 Endotype: view of Type 2/Th2 inflammation in early-onset, allergic asthma. iNOS, 
inducible nitric oxide synthase; PGD, prostaglandin D; TSLP, thymic stromal lymphopoietin; CCR, CC chemokine 
receptor; MUC5AC, mucin 5AC.  
 
 
B: Non-traditional (non-classical) TH 2 Endotype: possible underlying pathobiology in patients with nontraditional 
(non-classical) Type 2 inflammation associated with late onset, eosinophilic disease. ILC2; innate lymphoid cells.  
 
 
C: Mixed TH2 Endotype: possible underlying pathobiology in complicated/mixed Type 2 severe asthma (Th2/Th17 
pathway). APC, antigen-presenting cell; GCSF, granulocyte colony-stimulating factor; DUOX2, dual oxidase 2. 
 




The initial identification of Type 2 cytokine-
associated asthma relied on an invasive 
bronchoscopic approach. For this molecular 
phenotype to become more widely applicable, 
identification of more easily measured biomarkers 
was needed. 
Numerous less invasive biomarkers have now 
been reported in relation to a Type 2 asthma 
phenotype. Serum levels of periostin, the protein 
associated with one of the three epithelial Type 2 
signature genes, have been reported to better predict 
sputum eosinophilia than other biomarkers. 
Interestingly, the relation of serum periostin to 
epithelial expression of the Type 2 molecular 
signature has not yet been reported. The predictive 
value was maintained even in a multivariate 
approach, which included fractional exhaled nitric 
oxide (FeNO) and was seen in both CS-treated and 
-untreated patients. 
It also was reported to predict response to 
treatment with anti-IL-13 (lebrikizumab) 
molecularly targeted therapy17. 
Sputum assessment has also been used to less 
invasively identify this Type 2 Hi phenotype. The 
mean expression of the Type 2 cytokines IL-4, -5, 
and -13 in sputum was reported to strongly 
correlate with the Type 2 epithelial signature genes, 
CLCA1 and periostin (but not SERPINEB2), which 
are thought to be arising from epithelial cells in 
sputum and to predict both blood and sputum 
eosinophilia, at least in patients with milder asthma. 
The utility of this sputum Type 2 signature in more 
severe CS-treated patients or as a predictor of 
response to Type 2-targeted therapies remains to be 
determined 1, 22. 
Elevated levels of FeNO have been associated 
with asthma and allergy for many years. Inducible 
NO synthase (iNOS), the enzyme primarily 
responsible for generation of NO in the airway 
epithelium, is strongly induced by IL-13 in vitro, 
and FeNO is consistently decreased following 
treatment with anti- IL-4/-13 therapies17. It is also 
known to be upregulated by the Type 1 cytokine 
interferon-³ , such that elevated FeNO is not specific 
to Type 2 inflammation12. This may explain the 
observation that FeNO can be elevated in atopic 
healthy controls as well as severe CS-treated 
patients23. Although it has been associated with 
eosinophilic inflammation, selective reduction in 
blood and sputum eosinophils following anti-IL-5-
targeted therapy does not decrease FeNO, 
supporting important differences between these two 
Type 2 cytokine-associated biomarkers20. Whether 
differences in identification of Type 2 sub-
phenotypes or prediction of responses to different 
Type 2-targeted biological therapies will emerge 
remains to be investigated. 
 
The presence of type 2 molecular phenotypes is 
supported by responses to type 2-targeted 
therapies.  
Determining the clinical significance of any 
molecular phenotype requires evidence that the 
identified molecular pathway responds to targeted 
molecular therapies and that clinically meaningful 
responses occur. Trials of Type 2-targeted therapies 
for asthma were generally not successful in non-
phenotyped populations24. However, studies of 
Type 2 cytokine-directed therapies have confirmed 
the importance of these molecular pathways in 
predefined patients with Type 2 biomarker-
associated asthma and suggest that clinically 
identifiable phenotypes may be driven by common 
underlying molecular pathways. 
When a Type 2 biomarker is utilized to identify 
a Type 2 asthma phenotype, all recent studies of 
Type 2 cytokine targeted therapies have been 
clinically successful. Thus confirmation of 
biological importance of a molecular pathway to a 
clinically and molecularly identifiable disease is the 
first step toward identifying disease endotypes25. 
 
TH 2 asthma: confirming the role of IL-5  
In this regard, IL-5, a canonical Type 2 cytokine, is 
one of the most pro-eosinophilic cytokines yet 
identified. When mepolizumab, a monoclonal 
antibody to IL-5 that had failed in previous 
nonselective asthma studies, was targeted to 
patients with moderate to severe asthma with 
historical sputum eosinophilia, a significant 
reduction in asthma exacerbations occurred over a 
period of a year23. 
There were no effects on other phenotypic 
characteristics, such as symptoms or lung function. 
There was a small effect on airway wall thickening 
measured by CT scan observed, in line with the 
previously observed effect of reductions in 
extracellular matrix components, eosinophils, and 
TGF-²  expression in bronchoscopic biopsy 
specimens collected from patients with milder 
asthma23. Clinical characteristics of this 
eosinophilic IL-5-responsive phenotype included 
the presence of late-onset disease, nasal polyps, and 
sinus disease, clinical characteristics known to be 
related to eosinophilic inflammation25. 
A similar antibody to IL-5 (resilizumab) was 
evaluated in moderate to severe asthma with 
persistent high levels of sputum eosinophilia (e  3% 
on 2 occasions). There was a tendency for 
improvement in symptoms and lung function, but 
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the study was not of long enough duration to 
address exacerbations26. Most recently, anti-IL-5 
was targeted to eosinophilic systemic CS-dependent 
severe asthmatics18. Forty percent of these primarily 
adult-onset patients, eosinophilic despite systemic 
CS, were able to reduce their CS dose by >75% 
while maintaining asthma control and decreasing 
exacerbations compared with placebo. Interestingly, 
the remaining subjects had little overall difference 
compared with placebo, suggesting that IL-5 plays 
a critical role in some, but perhaps not all, 
eosinophilic asthmatic patients. Overall, these 
studies confirm the molecular relationship of the 
Type 2 cytokine IL-5 to an eosinophilic 
inflammatory process, with some suggestions that 
responsive patients (later onset, highly eosinophilic) 
may differ from the traditional (classic) early-onset 
Th2 molecular allergic phenotype (Fig. 3 B). 
 
A type 2 molecular phenotype: confirmation of a 
role for IL-4/-13:  
Like IL-5, IL-4 and -13 are reported to be increased 
in asthma24. However, associations with clinical 
characteristics other than disease severity or atopy 
have not been not reported. Therefore, it was 
perhaps not surprising that studies targeting IL-4, 
alone or in combination with IL-13, although 
efficacious in early small trials, were not successful 
in larger studies11 (Fig. 4). 
Despite these negative studies, and unlike anti-
IL-5, which had failed in an allergen challenge 
model in humans, a mutant IL-4 (pitrakinra) that 
blocked the IL-4 receptor complex and a 
monoclonal antibody to IL-13 showed efficacy in 
inhaled allergen challenge studies. These challenge 
studies suggested that targeting IL-4/-13 could be 
efficacious in the presence of a prototypical 
allergic/Type 2 inflammatory process12. 
These allergen challenge studies were followed 
by studies of patients with chronic asthma, in which 
Type 2 status was not initially addressed. An 
antibody to the IL-4 receptor was not effective in 
unphenotyped moderate asthma27, 28.  
Anti-IL-13 (lebrikizumab) was also only 
marginally effective in all enrolled patients with 
moderate to severe asthma23. However, 
lebrikizumab was more effective in improving lung 
function/forced expiratory volume in 1 s (FEV1) in 
patients with high serum periostin levels, a 
biomarker of a Type 2 phenotype, compared with 
those with low levels. Greater improvements in 
lung function were also seen in those patients with 
high compared with low FeNO levels, with the 
greatest improvements seen in those with both high 
periostin and FeNO28. Although there was a 
suggestion of marginal effects on asthma 
exacerbations, there were no effects on symptoms 
or asthma control, supporting a selective role of IL-
13 on the phenotypic characteristic of airflow 
limitation. Similar results were seen with the anti-
IL-13 antibody tralokizumab, which was min had 
greater efficacy in improving FEV1 in those 
patients with detectable sputum IL-13 levels25. 
Blood and sputum eosinophils (as Type 2 
biomarkers) were used to prospectively identify an 
eosinophilic moderate to severe asthma population 
for a trial of a monoclonal antibody to the IL-4 
receptor-± (dupilumab)26. Most patients were 
included on the basis of blood eosinophils 
e300/mm3 despite use of moderate- to high-dose 
inhaled CS and long-acting ² 2-agonists (LABA). In 
population of generally severe asthmatics, treatment 
with dupilumab resulted in an 87% reduction in 
protocol-defined exacerbations while improving 
asthma control, FEV1, asthma and rhinitic 
symptoms compared with placebo both when added 
to background therapy and when that therapy was 
withdrawn. 
 
Type 2 cytokine-associated molecular endotypes 
(Figure 3).  
Elements of a Type 2 signature can be identified 
over a range of asthma severity levels and 
treatments1,18. However, the characteristics 
associated with a Type 2 signature may differ by 
severity level and clinical phenotype, such that a 
Type 2 signature alone may not predict disease 
severity or associated clinical phenotype. Whereas 
it identifies a traditional early-onset allergic asthma 
phenotype in patients with milder/CS-naïve asthma, 
it may also associate with a late-onset, severe-CS-
dependent clinical phenotype29. Previous studies 
suggested that lung (tissue and sputum) eosinophils, 
as a Type 2 (IL-5) biomarker, were more prominent 
in adult-onset, less allergic, and more severe 
asthma, a group where anti-IL-5 appears to be quite 
effective3 (Fig. 3B). Interestingly, this adult-onset 
Type 2 molecular phenotype was also reported to 
be specifically associated with higher epithelial 
levels of eotaxin-2/CCL24, one of the potent pro-
eosinophilic chemokines compared with early onset 
allergic asthma, potentially suggesting a mechanism 
for the increased eosinophilia21. In contrast, an anti-
IL-5 was ineffective in an allergen challenge model, 
whereas inhibitors of IL-4/-13 significantly 
impacted these responses2. Thus, although the 
contributions of different Type 2 cytokines to 
disease may vary by clinical phenotype, an 
improved understanding of which phenotype is 
more strongly linked to which anti-cytokine will 
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clearly advance our understanding of molecular 
phenotypes. 
The presence of Type 2 molecular sub-
phenotypes is also supported by in vitro 
lymphocytic expression studies, which report 
differences in expression of Type 2 cytokines by 
cellular phenotype. IL-4, -5, and -13 may arise from 
different cell types, with IL-5 expression being 
associated with both a more differentiated (“super”) 
Th2 lymphocyte9. Alternatively, it (as well as IL-
13) can be expressed by ILC2 cells. Thus a sub-
phenotype identified by high levels of IL-5 with 
lesser association with IL-4 (and perhaps IL-13) 
potentially exists, which could selectively respond 
to IL-5-targeted therapy (Fig. 3C). However, this 
molecular pathobiology has not yet been confirmed 
in vivo29. 
In contrast, BAL eosinophilia was less in two 
clusters of early-onset asthmatics but more allergic 
mild to severe asthmatics than in the late-onset 
cluster. The efficacy of biologics targeted to IL-4/-
13 in allergen challenge studies suggests that IL-4/-
13-targeted therapies may be more effective in this 
Type 2 subphenotype, where eosinophilia is less 
central to disease outcomes (Fig. 3A). 
 
 
The increasingly granular umbrella for Type 2 cytokine-associated asthma molecular phenotypes, all of which encompass some Type 
2 inflammatory biomarkers. [CS, corticosteroid; FeNO, fractional exhaled NO] 
 
Figure 4. Asthma endotypes in clinical context29 
 
Importantly, however, a fourth patient cluster 
identified the most severe patients with the most 
systemic CS use. In these patients, BAL eosinophils 
and neutrophils were persistently elevated, similar 
to previously reported associations of some patients 
with severe asthma with a mixed granulocytic 
inflammation27. FeNO (as an additional Type 2 
biomarker) was also highest in this severest patient 
cluster, despite more modest elevations in BAL 
eosinophils and low levels of blood eosinophils, 
supporting inconsistent associations of these Type 2 
biomarkers. These inconsistent relationships 
between Type 2 cytokine biomarkers were also seen 
in a multivariate regression analysis of severe 
asthmatic patients in the SARP cohort. This 
analysis identified elevated FeNO as the most 
significant independent risk factor for chronic 
systemic CS use, despite very low blood eosinophil 
levels13. The presence of this apparently more 
complex Type 2 severe asthma subphenotype 
(neutrophils, lung eosinophilia, and high FeNO 
despite systemic CS) strongly supports a 
contribution from additional molecular processes, 
including those related to autoimmunity and Type 1 
and perhaps Type 17 cytokines (Fig. 3C).  
The Th2/Th17 predominant endotype of severe 
asthma is associated with increased IL1² , C3 and 
their downstream signaling molecules in 
bronchoalveolar lavage as manifested by increased 
expression of MEK (mitogen-activated protein 
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kinase kinase). The expression of two MEK-
inducible and steroid resistance-inducing 
transcription factors—c-Fos and JunB was elevated 
in Th2/Th17 cells. The MEK inhibitor trametinib 
(anticancer treatment) inhibited Th2/Th17 pathway. 
Also; BAL with Th2/Th17 cells had increased 
Interferon regulatory factor 4  (IRF4) and Batf -
JUN family protein complexes, two transcription 
factors that are associated with chromatin 
reorganization and transdifferentiation of Th2 and 
Th17 cells5, 29. 
This group may include the recently defined 
subset of patients with asthmatic granulomatosis, 
consisting of patients with severe, systemic CS-
dependent asthma with elevations in FeNO, blood 
and lung eosinophils, as well as interstitial 
granulomas14. Intriguingly, a family history of 
autoimmune disease is common in these patients, 
and they generally respond to non-steroidal 
immunomodulating therapies, including 
azathioprine (Immuran) and mycophenolate 
 (CellCept or Myfortic). 
Persistent elevations of FeNO despite systemic 
CS in patients with severe asthma have also been 
seen in association with elevations of concomitant 
Type 1 cytokines (interferon-³  in particular). IL-4 
and/or IL-13 in combination with interferon-³  
synergistically enhance iNOS expression19. This 
combination contributes to a high degree of nitro-
oxidative stress in the airway epithelium and, 
potentially, to severe disease5. 
The specific contribution of Type 1 
inflammation to certain Type 2 sub-phenotypes 
remains to be determined but may make this very 
severe Type 2 sub-phenotype more refractory to 
both CS and Type 2-directed therapy than other 
phenotypes. This complex immunity may explain 
the inability of another monoclonal antibody to IL-
13 to improve outcomes in patients with more 
severe asthma than those previously studied24. 
 
Non-Type 2 cytokine-associated asthma 
Although substantial studies have been made in 
identifying molecular markers and even nascent 
molecular sub-phenotypes of Type 2 cytokine 
associated asthma, the same cannot be said for non-
Type 2 asthma. In fact, the very definition of non-
Type 2 asthma is the absence of any evidence for 
activated Type 2 pathways (low levels of FeNO, 
eosinophils, or Type 2 signature genes), without 
links to other molecular pathways/phenotypes1.  
Thus identification of these non-Type 2 
phenotypes is limited by an overall lack of 
association between clinical characteristics, 
responses to therapy, and underlying pathology, 
including the presence of lung neutrophils. Except 
for the poorly studied smoking-associated asthma, 
the underlying disease present in most non-Type 2 
asthmatics may be less severe on the whole than 
those with persistent Type 2-related inflammation30. 
Rather, co-morbidities, including obesity, sinus 
disease, gastroesophageal reflux, and vocal cord 
dysfunction may make it appear more severe11, 20. 
Interestingly, one of the unifying characteristic of 
these non-Type 2 phenotypes, even in milder 
disease, is their relative CS unresponsiveness, 
perhaps attributable to lack of CS-responsive 
inflammatory elements10. 
 
Potential molecular phenotypes related to 
obesity 
Obesity in Western societies has become epidemic, 
with several epidemiological studies suggesting that 
obesity predisposes to asthma7. Additionally mouse 
studies suggest that obese mice (obese because of 
leptin or leptin receptor deficiency) develop more 
AHR to ozone or allergen challenge, but the 
relationship to inflammatory mediators and cellular 
inflammation is less clear4, 8. The effect on AHR 
does not appear to be leptin dependent, and, similar 
to obese humans with asthma, the reasons for the 
increase in AHR are not clear1, 15. 
Whether obesity causes a distinct molecular 
asthma phenotype or whether it worsens existing 
disease in humans is controversial. One study 
reported that obesity in childhood onset asthma is 
directly proportional to duration of disease, 
suggesting that it is a co-morbidity but not a driver 
of disease6. In contrast, the degree of obesity in 
asthma that develops later in life is not related to 
disease duration. Rather, it associates strongly with 
symptoms, health care utilization, and molecularly 
with low FeNO, eosinophils, and IgE levels9, 
supporting a lack of Type 2 immune background. 
Supporting this, weight loss through bariatric 
surgery had a greater therapeutic effect on late-
onset/non-Type 2 obese asthma compared with 
early-onset/Type 2-associated severe asthma27. 
Although highly preliminary, these studies 
suggest that obesity, with its associated metabolic 
and oxidative stress, may contribute to the 
development of a late-onset obese asthma 
molecular phenotype. Although there are few 
specifics regarding the oxidative stress pathway in 
obese asthma, obesity in general induces a higher 
oxidative stress level15. If there is an underlying, 
perhaps genetic increase in AHR, the addition of 
oxidative stress could make the condition worse. 
Preliminary studies have suggested that a 
compound increased in obesity and metabolic 
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syndrome, asymmetric dimethylarginine (ADMA), 
is increased in late-onset obese asthma7. ADMA is 
a known inhibitor of iNOS, which can switch iNOS 
from metabolizing arginine to NO to generating 
superoxide, which could then contribute to 
oxidative stress observed in late-onset obese 
asthma1, 8. Confirming the importance of this or 
other oxidative pathways to obese, non-Type 2 
molecular (perhaps metabolic) phenotype of asthma 
will require specific antioxidative/ metabolic 
pathway approaches29. 
 
Do IL-17 or TNF-± contribute to molecular 
phenotypes? 
The lack of CS response in association with 
neutrophilia has suggested that the IL-17 pathway 
may be important in some poorly controlled non-
Type 2 molecular phenotypes2, 26. IL-17 has been 
related to neutrophilia and steroid resistance, as 
well as enhanced allergic/complement-associated 
responses in mouse models. Although one study 
suggested a relation to smoking-associated asthma, 
with its generally neutrophilic phenotype, other 
recent data suggest that an active Type 17 (and 
neutrophilic) immune process may actually 
contribute to less severe disease1. In fact, a 
monoclonal antibody to the IL-17 receptor, which 
inhibits all isoforms of IL-17, including the Type 2-
associated cytokine IL-25 (brodalumab), was 
modestly efficacious only in patients with asthma 
with a robust bronchodilator response14.  
There was no relation to neutrophilic or 
eosinophilic inflammation. Similarly, TNF-± and 
related Toll-like receptor pathways have been 
suggested to contribute to neutrophilic asthma by 
gene expression array profiling6. However, the 
confirmation of the relevance of these pathways to a 
clinically identifiable phenotype that responds to 
selective molecularly targeted therapies does not yet 
exit. The few studies that have evaluated anti-TNF-
± approaches in larger studies of moderate to severe 
asthma were unable to demonstrate efficacy in the 
total population and unable to identify neutrophilia 
(or eosinophilia) as a specific responder phenotype. 
Interestingly, subgroup analyses of the efficacy of 
anti-TNF-± identified robust bronchodilator 
responsiveness, later-onset disease, and sinusitis as 
elements of a responder phenotype in very severe 
asthma10. However, despite the association of obese 
asthma with increases in TNF-±, the efficacy of the 
anti-TNF-±, golimumab, was not modified by 
obesity28. Thus the relevance of specific 
immunological factors to some phenotypes of non-
Type 2 asthma remains unknown. 
The molecular underpinnings of smoking-related 
asthma are also not clear. It is likely that, in some 
cases, a Type 2 immune process was and still is 
present, perhaps exacerbated by effects of oxidative 
stress, neutrophilic inflammation, epithelial 
damage, and infection, particularly in those with 
early-onset disease18. Interestingly, active smoking 
lowers FeNO levels although whether the 
mechanisms include inhibition of Type 2 cytokine 
pathways, increased levels of nitrative stress = 
reactive nitrogen species (RNS) (as opposed to 
FeNO), or simply activation of non- Type 2 
cytokine pathways, including neutrophilic 
processes, is not clear27,30. 
 
Conclusion 
The view that bronchial asthma (BA) is a single 
disease is rapidly disappearing.  Recognition of the 
heterogeneity of BA together with the definition of 
clinical phenotypes, pathogenetic endotypes and the 
development of novel biomarkers has opened a new 
chapter in pediatric asthma clinical care.  
Although the vast majority of asthmatic children 
are well controlled with guideline based anti-
inflammatory therapies, there is a strong medical 
need for improved therapies in the remaining 
portion of patients.  
As better understanding of asthma phenotypes 
and endotypes emerges, it is hoped that, in the 
future, the findings will enhance the development 
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